Minerva Neurosciences | NERV - Dochód Netto





Dochód Netto Zmiana Data
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Adma Biologics USD 49.38M 12.95M 2025-12
ALKERMES USD -66.48M 115.82M 2026-03
Alterity Therapeutics Limited AUD -6.3M 525.41K 2025-12
AstraZeneca USD 3.08B 754M 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Cipla INR 5.55B 1.21B 2026-03
Clal Biotechnology ILS -6.17M 15.56M 2022-12
Compugen USD 56.84M 63.82M 2025-12
CSL USD 401M 96.5M 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Esperion Therapeutics USD 61.83M 93.16M 2025-12
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Grifols EUR 114.37M 34.03M 2025-12
Halozyme Therapeutics USD 150.05M 291.64M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
J&J USD 5.24B 119M 2026-03
Merck USD -4.24B 7.2B 2026-03
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Novartis USD 3.16B 747M 2026-03
Novavax USD 17.53M 219.91M 2025-12
Pfizer USD 2.69B 4.34B 2026-03
Roche Holding CHF 5.47B 1.76B 2025-12
Sanofi EUR 1.61B 2.42B 2026-03
Takeda JPY -24.32B 127.96B 2026-03
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12